Norbert Galldiks, Ian Law, Whitney B Pope, Javier Arbizu, Karl-Josef Langen
Journal: NeuroImage. Clinical 2017;13():386-394
PMID: 28116231
Routine diagnostics and treatment monitoring of brain tumors is usually based on contrast-enhanced MRI. However, the capacity of conventional MRI to differentiate tumor tissue from posttherapeutic effects following neurosurgical resection, chemoradiation, alkylating chemotherapy, radiosurgery, and/or immunotherapy may be limited. Metabolic imaging using PET can provide relevant additional information on tumor metabolism, which allows for more accurate diagnostics especially in clinically equivocal situations. This review article focuses predominantly on the amino acid PET tracers C-methyl-l-methionine (MET), -(2-[F]fluoroethyl)-l-tyrosine (FET) and 3,4-dihydroxy-6-[F]-fluoro-l-phenylalanine (FDOPA) and summarizes investigations regarding monitoring of brain tumor therapy.
Full Text Sources:
Medical:
Other Literature Sources:
Miscellaneous:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.